In recent years, the pharmaceutical and biotech industries have been concerned about the global activities of large CRO companies (contract research organizations).
Pharmaceutical and biotech companies conducted surveys and sought the opinions of large and medium-sized CROs from sponsors and end customers. It goes without saying that the industry has been volatile for some time as Covid-19 has had a major impact on outsourcing relationships in the industry.
The world's pharmaceuticals and biotechs have expressed concern about working with large CROs, saying that the "one-stop shop" model is no longer a cost-effective business model.
Clinical research is rapidly moving into new areas, and large-scale biotechs need to revisit past experiences. Among the problems of large CRO companies, it should be noted the lack of individual attention to the client, concerns about high costs for the development of devices, and disruptions in the work of CRO teams, which affects the time of work.
Global surveys show that pharmaceutical and biotech companies prefer mid-sized CROs because of personalized service. They are perceived more favorably for cooperation by sponsors due to their flexibility, individual attention.
Sponsors are looking for transparent communication, responsiveness, a proactive, personalized approach. Customers don't want to be treated as just statistics. They want a true partnership, including regular access to CRO senior executives, their scientific experts, and certain assurances from them.
Clinical research statistics in the field of monitoring CRO companies predict that a global transition from large to medium-sized CRO companies is expected within the next three years.
Comments